Concepedia

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Julien Mazières, Sylvie Lantuéjoul, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, V. Gounant, Martine Antoine,

Clinical Lung Cancer · 2019 · 63 citations · 13 references

DOIFull text

Open access

Concepts

References

13

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.2K citations · Full text

, , +8

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

, , +5

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

Guocan Wang, Xin Lü, Prasenjit Dey et al. · Cancer Discovery · 2015 · 536 citations · Full text

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

, , +5

PD-L1 expression in small cell neuroendocrine carcinomas

Anne M. Schultheis, Andreas H. Scheel, Luka Ozretić et al. · European Journal of Cancer · 2015 · 236 citations · Full text